News
-
-
-
COMMUNIQUÉ DE PRESSE
HIGHCO : Mise à disposition des documents préparatoires à l’Assemblée Générale
Annonce de l'assemblée générale mixte de HighCo le 19 mai 2025 avec modalités de participation et mise à disposition des documents préparatoires. HighCo, expert en marketing et communication, cotée sur Euronext Paris -
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali
Secarna Pharmaceuticals appoints Prof. Dr. Dario Vignali to Scientific Advisory Board, enhancing expertise in oncology research and immunotherapy strategies for solid tumors -
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Jaguar Health to host investor webcast on crofelemer's impact on MVID and SBS-IF patient experience, with results of investigator-initiated trial by Dr. Miqdady presented at ELITE PED-GI Congress in Abu Dhabi -
COMMUNIQUÉ DE PRESSE
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Mainz Biomed provides Q1 2025 corporate update on FDA premarket approval path, including study enrollment, partnership with Liquid Biosciences and labor team w ag, and product launches. CEO Guido Baechler comments on progress -
